SCHEMBL3774342

SCHEMBL3774342

Cc1cccc(C2(O)CCN(CC(=O)N3CCN(C4CCCC4)CC3)CC2)c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.46
HTT P42858 1/20 0.46
KDM4E B2RXH2 4/20 0.45
ALDH1A1 P00352 3/20 0.45
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
OPRM1 P35372 3/20 0.42
OPRK1 P41145 3/20 0.42
OPRL1 P41146 3/20 0.42
OPRD1 P41143 1/20 0.42
GAA P10253 1/20 0.40
TSHR P16473 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
PARP1 P09874 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3772438 0.98 NPSR1 (0.44) NPSR1HTTKDM4EALDH1A1CYP2D6
SCHEMBL13005268 0.88 HTT (0.49) NPSR1HTTKDM4EALDH1A1CYP2C19
SCHEMBL13005270 0.85 ALDH1A1 (0.48) HTTKDM4EALDH1A1CYP2C19MEN1
SCHEMBL3771977 0.85 OPRL1 (0.60) KDM4ECYP2D6MEN1KMT2ASMN1; SMN2
SCHEMBL3777229 0.85 KMT2A (0.60) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL3767778 0.85 LMNA (0.45) NPSR1HTTKDM4EALDH1A1CYP2D6
SCHEMBL3772583 0.83 OPRL1 (0.58) KDM4ECYP2D6MEN1KMT2ASMN1; SMN2
SCHEMBL3769340 0.81 KDM4E (0.49) NPSR1HTTKDM4EALDH1A1MEN1
SCHEMBL3765913 0.80 ALDH1A1 (0.57) HTTKDM4EALDH1A1MEN1KMT2A
SCHEMBL3760871 0.80 MEN1 (0.56) NPSR1HTTKDM4EALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 NPSR1 357/4885HTT 608/4885KDM4E 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.